Clinical Trial Record

Return to Clinical Trials

Usefulness of Smartphone Application for Improving Nutritional Status of Pancreatic Cancer Patients


2017-02-22


2018-03-27


2018-03-27


40

Study Overview

Usefulness of Smartphone Application for Improving Nutritional Status of Pancreatic Cancer Patients

Malnutrition of hospitalized patients is reported in the range of 20-60% according to the definition and assessment method of malnutrition. In particular, the incidence of malnutrition in cancer patients is high up to 30-85%. Gastrointestinal disease is related to the digestion and absorption of nutrition therefore malnutrition rate of those patients is relatively high. Careful management of nutrition support is needed. Malnutrition causes dysfunction of the mesenteric membrane, immune function impairment, decreased function of major organs such as liver, kidney and heart and alteration in pharmacodynamics. It could also increase infection rate and complications of chemotherapy, delay recovery time, so that increase morbidity, mortality and length of hospital stay. Proper nutrition management reduces malnutrition prevalence and medical costs of hospitalized patient, therefore nutrition screening and evaluation is necessary. The recent spread of smartphones has made it easier to record and evaluate meals, which are used in the diet market for weight loss through meal records and feedback based on smartphone applications. This approach is also expected to benefit patients with gastrointestinal cancer, where proper nutrition and feedback are important. In particular, pancreatic cancer, the worst intractable cancer of mankind, is digestive cancer with the most severe muscle mass reduction and nutritional deterioration after diagnosis.

N/A

  • Pancreatic Cancer
  • OTHER: Smart phone application(NOOM)
  • OTHER: Non-user
  • 1-2016-0061

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2019-09-27  

N/A  

2019-09-27  

2019-09-27  

N/A  

2019-09-30  

2019-09-30  

N/A  

2019-09  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Other


Allocation:
Randomized


Interventional Model:
Parallel


Masking:
None


Arms and Interventions

Participant Group/ArmIntervention/Treatment
OTHER: Smart phone application(NOOM)

OTHER: Smart phone application(NOOM)

  • The study population included first diagnosis of pancreatic cancer patients within 3 months of pancreatic cancer center visit, and randomly assigned to the use of Noom user group and non-use group. A total of 40 patients, 20 from each group, were used to
OTHER: Non-user

OTHER: Non-user

  • The patients dose not use Noom application. A total of 40 patients, 20 from each group, were used to examine nutritional status (PG-SGA), blood index analysis, and quality of life (EORTC QLQ) at 0, 4, 8, and 12 weeks. The purpose and contents of this stud
Primary Outcome MeasuresMeasure DescriptionTime Frame
PG-SGA(Patient-Generated Subjective Global Assessment)A patient-generated subjective global assessment (PG-SGA) for oncology patients has been developed by Ottery. This tool has two sections-a medical history section that is completed by the patient, and a physical assessment section that is completed by nursing, medical, or dietetic staff. The medical history section includes additional questions regarding the presence of oncology nutrition impact symptoms.12 weeks
EORTC Questionnaires - Quality of LifeThe European Organization for Research and Treatment(EORTC) questionnaire was designed to measure cancer patients' physical, psychological and social functions. The questionnaire is composed of 5 multiitem scales (physical, role, social, emotional and cognitive functioning) and 9 single items(pain, fatigue, financial impact, appetite loss, nausea/vomiting, diarrhea, constipation, sleep disturbance and quality of life).12 weeks
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Skeletal muscle index changeCross-sectional skeletal muscle area (SMA, cm2) at this level is highly correlated with total body skeletal muscle mass. Adjustment of SMA for height2 results in skeletal muscle index (SMI, cm2/m2), a measure for relative muscle mass. Using skeletal muscle index change we evaluated sarcopenia in pancreatic cancer patients.8 weeks

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
20 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1) Among patients with pancreatic cancer who visited Severance Hospital of Yonsei University
    1. Patients who received the explanation from the investigator and agreed to the written consent of the subject 2. Men or Women aged 20 to 70
    2) First diagnosed with pancreatic cancer within 3 months 3) Patients scheduled to undergo first-line chemotherapy after the diagnosis of pancreatic cancer
    Exclusion Criteria:
    1. Those who have or had a history of abdominal surgery within the past 1 year 2. Those who have an acute illness (pneumonia, sepsis, shock, etc.) and have an infection at the time of registration 3. chronic liver disease and chronic obstructive pulmonary disease 4. Patients with nutrient absorption disorder due to gastrointestinal mucosal diseases (ulcerative colitis, Crohn's disease, acute and chronic diarrhea, etc.) 5. Severe disease patients (heart failure, liver failure, kidney failure and hemodialysis, etc.) 6. Those who are pregnant or breastfeeding 7. Those who have used steroids within the last one month 8. Patients diagnosed of peritoneal seeding or suspected GI obstructive sign 9. Those who are already taking nutritional supplements

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Keum J, Chung MJ, Kim Y, Ko H, Sung MJ, Jo JH, Park JY, Bang S, Park SW, Song SY, Lee HS. Usefulness of Smartphone Apps for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2021 Aug 31;9(8):e21088. doi: 10.2196/21088.